EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Molecular Docking and Dynamic Simulations Reveal Glycyrrhizic Acid Alleviates Allergic Rhinitis in Rats by Inhibiting the TLR4/NF‐κB/IL‐1β Pathway

Jianquan Huang iD, Xinyue Ren iD, Xiaojin Chen iD, Xiang Zheng iD

Journal of Immunology Research · 2026-01 · 2026 (1)

DOI: 10.1155/jimr/6032689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 10.08.2026. Verfasst von Jianquan Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hangzhou Children's Hospital, Hangzhou 310014, Zhejiang, China, hzch.org. Hauptthemen laut MEDLINE: Glycyrrhizic Acid, Toll-Like Receptor 4, Rhinitis, Allergic, Anti-Inflammatory Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hangzhou Municipal Science and Technology Special Project for Supporting the Development of Biopharmaceutical and Health Industries, Construction Fund of Key Medical Disciplines of Hangzhou, Hangzhou Children's Hospital Institutional Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic rhinitis (AR) is a prevalent chronic inflammatory nasal disorder with suboptimal current therapies. Glycyrrhizic acid (GA), a bioactive triterpenoid from Glycyrrhiza uralensis , exerts well‐documented antiinflammatory effects, and preliminary evidence indicates its efficacy in alleviating airway inflammation in AR models. However, two critical knowledge gaps remain unaddressed: whether GA directly binds to core proteins of the toll‐like receptor 4 (TLR4)/nuclear factor‐kappa B (NF‐κB)/IL‐1β inflammatory pathway, and whether this binding mediates GA’s therapeutic effects in AR have not been systematically verified by integrated computational and in vivo experiments.

Methods

An ovalbumin (OVA)‐induced AR rat model was established. GA was administered intranasally for seven consecutive days. Behavioral observations, histopathological examination, and serum cytokine detection were performed to evaluate AR‐related symptoms and immune imbalance. Molecular docking was employed to assess the binding affinity between GA and four key proteins in the TLR4 pathway (TLR4, myeloid differentiation primary response 88 [MyD88], NF‐κB, and IL‐1β). About 100 ns molecular dynamics (MD) simulations were further conducted to validate the stability of the GA–protein complexes. Immunohistochemistry and RT‐qPCR were used to verify the expression of pathway‐related proteins and cytokines in nasal mucosal tissues.

Results

GA significantly reduced sneezing, rhinorrhea, and nasal mucosal pathological damage in AR rats. It restored the T helper 1 (Th1)/Th2 immune balance by suppressing Th2 cytokines (IL‐4 and IL‐13) and enhancing Th1 cytokines (interferon‐gamma [IFN‐γ] and IL‐2). Molecular docking results showed that GA bound strongly to all four target proteins, with the highest affinity for IL‐1β (−9.3 kcal/mol) and TLR4 (−7.6 kcal/mol). MD simulations confirmed the stable conformational dynamics of the GA–IL‐1β and GA–TLR4 complexes. In vivo experiments further demonstrated that GA significantly downregulated the expression of TLR4, MyD88, NF‐κB, and IL‐1β in nasal mucosa and reduced the levels of downstream proinflammatory cytokines (TNF‐α and IL‐6).

Conclusions

GA alleviates AR symptoms by directly binding to core proteins of the TLR4/NF‐κB/IL‐1β pathway, inhibiting pathway activation, restoring Th1/Th2 immune balance, and suppressing inflammatory responses. This study provides structural and functional evidence supporting GA as a promising targeted therapeutic candidate for AR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycyrrhizic AcidToll-Like Receptor 4Rhinitis, AllergicAnti-Inflammatory AgentsAnimalsMolecular Docking SimulationRatsNF-kappa BSignal TransductionMolecular Dynamics SimulationDisease Models, AnimalInterleukin-1betaOvalbuminMaleCytokinesMyeloid Differentiation Factor 88Nasal MucosaHumansRats, Sprague-Dawley

Stichwörter der Autor:innen

TLR4/NF-κB/IL-1β pathwayallergic rhinitisglycyrrhizic acidmolecular dockingmolecular dynamics simulation

Substanzen

Glycyrrhizic AcidToll-Like Receptor 4NF-kappa BInterleukin-1betaTlr4 protein, ratOvalbuminCytokinesMyeloid Differentiation Factor 88Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Hangzhou Children's Hospital, Hangzhou 310014, Zhejiang, China, hzch.org.
  • Department of Pharmacy, Hangzhou Maternity and Child Health Care Hospital, Hangzhou 310008, Zhejiang, China.
  • Pediatric Research Institute, Hangzhou Children's Hospital, Hangzhou 310014, Zhejiang, China, hzch.org.

ORCID-Profile: Jianquan Huang, Xinyue Ren, Xiaojin Chen, Xiang Zheng

Förderung

  • Hangzhou Municipal Science and Technology Special Project for Supporting the Development of Biopharmaceutical and Health Industries
  • Construction Fund of Key Medical Disciplines of Hangzhou
  • Hangzhou Children's Hospital Institutional Research Project

Zitieren

APA

Huang, J., Ren, X., Chen, X., & Zheng, X. (2026). Integrated Molecular Docking and Dynamic Simulations Reveal Glycyrrhizic Acid Alleviates Allergic Rhinitis in Rats by Inhibiting the TLR4/NF‐κB/IL‐1β Pathway. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/6032689

Vancouver

Huang J, Ren X, Chen X, Zheng X. Integrated Molecular Docking and Dynamic Simulations Reveal Glycyrrhizic Acid Alleviates Allergic Rhinitis in Rats by Inhibiting the TLR4/NF‐κB/IL‐1β Pathway. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/6032689

BibTeX
@article{Huang2026,
  author = {Huang, Jianquan and Ren, Xinyue and Chen, Xiaojin and Zheng, Xiang},
  title = {Integrated Molecular Docking and Dynamic Simulations Reveal Glycyrrhizic Acid Alleviates Allergic Rhinitis in Rats by Inhibiting the TLR4/NF‐κB/IL‐1β Pathway},
  journal = {Journal of Immunology Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jimr/6032689}
}
Kostenlos starten →